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Abstract
Chronic wounds do not follow the usual wound healing process; instead, they are stuck
in the inflammatory or proliferative phase. This is particularly evident in large, massive
wounds with considerable tissue loss, which become senescent and do not epithelial‐
ize. In these wounds, we need to remove all the factors that prevent or delay normal
wound healing.  After  that,  soft  tissue  granulation  is  stimulated  by  local  negative
pressure  therapy.  Lastly,  after  the  granulation  is  completed,  the  epithelialization
process must be activated. Although a plethora of wound dressings and devices are
available, chronic wounds persist as a unresolved medical concern. We have been using
frozen amniotic membrane (AM) to treat this type of wounds with good results. Our
studies have shown that AM is able to induce epithelialization in large wounds that
were unable to epithelialize. AM induces several signaling pathways involved in cell
migration and/or proliferation. Among those, we can highlight the mitogen‐activated
protein  kinase  (MAPK)  and  Jun  N‐terminal  kinase  (JNK)  signaling  pathways.
Additionally, AM is able to selectively antagonise the anti‐proliferative effect of TGFß
by modifying its genetic program on keratinocytes. The combined effect of AM on
keratinocytes, promoting cell proliferation/migration and antagonising TGFß‐effect, is
the perfect combination allowing chronic wounds to progress into epithelialization.
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1. Introduction
The evolution of knowledge about the biology of wound healing makes it possible to predict
the sequence and prognosis of the events that occur in this complex process. However, there
are wounds in which healing can be either prolonged over time or not fully achieved [1, 2].
Therefore, The keys to providing adequate and efficient treatment involve identifying, as soon
as possible, the combination of either internal or external factors that contribute to the
complexity of the wound and affect the healing process, and to detect at an early stage when
it is likely that a wound would be slow or difficult to heal.
The actions undertaken should be aimed at reducing the aspects that lead to complexity,
including factors related to the patient, the wound, relationships with healthcare personnel,
and available resources. Only by assessing and understanding the interaction between these
factors and their effect on healing will it be possible to develop efficient and appropriate
strategies for improving results. Similarly, certain characteristics of the wound, such as its
anatomical location, time duration, size, depth, and the state of the wound bed, are correlated
with adequate healing [3–5].
The presence of necrotic tissue, crusts, slough, or foreign bodies in the wound bed, which are
all obstacles for wound assessment, can lead to a delay in healing, and they can also be a focus
of infection. Therefore, it is important to provide frequent, extensive, and efficient debridement
until healthy tissue is found [6]. There are other situations that can have an influence and cause
healing to fail, such as ischemia. Poor perfusion deprives tissue of an efficient oxygen and
metabolic exchange, and causes an increase in vascular permeability, leukocyte retention,
synthesis and the liberation of oxygen free radicals and proteolytic enzymes [7]. Inflammation
in chronic wounds brings about a prolongation in healing time, resulting in an exacerbated
inflammatory reaction, which in turn causes the hyperproduction of pro‐inflammatory
cytokines and proteolytic enzymes. This activity is combined with a decrease in the secretion
of metalloproteinase tissue inhibitors, and it intensifies as the wound bed pH alters. As a
consequence, we find that in the wound bed there is a sustained inflammation with matrix
degradation, a limited bioavailability of growth factors and intense fibroblast aging, all of
which reduce tissue repair, cell proliferation, and angiogenesis [8, 9].
In the same way, chronic wounds are characterized by the presence of one or more bacterial
strains, with antibiotic‐resistant microorganisms, and the presence of biofilms within which
the bacteria are protected against the action of the silver‐based antimicrobials [10–13].
The initial response to treatment is indicative of the viability of the tissue and its capacity to
heal. When a patient’s wound does not heal in the planned period of time using conventional
treatment, it is essential to reassess the patient and modify the therapeutic guidelines [14, 15].
Thus, tissue wound healing usually follows a predictable sequence, although in some cases, it
is prolonged over time or it is never achieved. The wound healing process is the result of a
complex interaction between the patient and wound factors, the treatment adopted, and the
skills and knowledge of healthcare professionals. Only by carrying out a detailed initial
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assessment and repeated treatment assessment will it be possible to identify the factors that
contribute to the complexity of the wound and to assess its potential state. The challenge for
professionals is to utilize the most efficient therapeutic strategies at the right time and in the
most cost‐effective way, in order to reduce the complex nature of wounds, to treat the symp‐
toms, and whenever possible, to achieve wound healing.
2. How should chronic and complex soft‐tissue wounds be managed?
2.1. Management and treatment strategies
Chronic and complex soft‐tissue wounds usually involve difficult healing, which means that
they require an appropriate management‐treatment strategy using a comprehensive and
dynamic approach, applying new therapies to confront this old problem: wound healing [16].
In order to carry out this comprehensive approach, we should take into account the complex
nature of the wound and its healing, its relationship with psychosocial factors and delays in
wound healing, together with the economic cost for the patient, family, community, and the
healthcare system. The steps to follow in order to achieve this approach should take into
account the complete assessment of the patient, the control of causal factors, general healthcare,
and the preparation of the wound bed.
2.2. Preparation of the wound bed
The preparation of the wound bed is an essential and dynamic process that provides an
appropriate framework for a structured approach to wound management. This notion stresses
a comprehensive and systematic approach with the aim of assessing and eliminating barriers
to the normal wound healing process. It develops the appropriate treatment strategies to be
directed at the patient in general and for treating the underlying condition causing the wound.
Its objective is to create an optimum healing setting, a well‐vascularized wound, with a stable
and balanced bed in terms of exudate production, aimed at reducing scar healing time and
facilitating the efficiency of other therapeutic measures. The wound bed should be prepared
in each phase of the wound healing process following an agreed‐upon procedure.
The “Tissue, Inflammation‐infection, Moisture, Edge” (T.I.M.E.) scheme, proposed by the
European Wound Management Association (EWMA), is based on the research of the Interna‐
tional Wound Bed Preparation Advisory Board (IWBPAB), which established an algorithm
through the development of the acronym T.I.M.E., whose objective is to describe the charac‐
teristics of chronic wounds during wound bed preparation. Following on from this, the concept
was updated by placing emphasis on the treatment of the cause of the wound and general
patient factors during treatment, before dealing with local wound factors. This algorithm
consists of four components that cover the different physiopathological alterations present in
chronic wounds: the management and conditioning of non‐viable tissue, the monitoring of
inflammation and infection, the disequilibrium of moisture due to excess exudate, and the
stimulation and progression of the wound edges. So we can see that the T.I.M.E. framework
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involves the overall strategies that can be applied to the management of different kinds of
wound with the aim of maximizing the ability to heal wounds [16–18] (Figure 1).
Figure 1. Complex and traumatic soft-tissue wound. Management and treatment of wound bed.
Wound treatment is initiated with a hydrodynamic washing using 0.9% saline solution at room
temperature, with a 1–4 kg/cm effective washing pressure, without any damage being caused
(a 20-ml syringe, with a 0.9-mm-diameter catheter), and the surrounding area is washed with
a soapy antiseptic solution consisting of chlorhexidine digluconate.
For the monitoring of the non-viable tissues (necrotic tissue, crust, slough, and foreign bodies),
episodic or continuous debridement is carried out until healthy tissue is found. It can be
surgical, using tangential hydrodissection (Versajet™Plus, Smith & Nephew, London, United
Kingdom); enzymatic, applying exogenous enzymes locally (collagenase, fibrolysine, trypsin,
or chymotrypsin); chemical (cadexomer iodine); autolytic (due to the conjunction of three
factors: hydration of the bed, fibrinolysis and the action of the endogenous enzymes on the
devitalized tissue); or osmotic (hyperosmotic solutions). On occasions, an instillation therapy
can also be used (VeraFlo™, KCI, Acelity LPI, San Antonio, TX) either in deep wounds with a
viscous exudate or in uncontrolled infections on prosthetic materials, in order to eliminate the
biofilm, reduce the pain, and reactivate healing. A noninvasive treatment option, for the
debridement of chronic wounds, is low-frequency guided ultrasound [3].
In the management of the bacterial load (a contaminated or colonized lesion, with critical or
infected colonization), foci of local and/or systemic infection have to be removed, which is why
it is necessary to clean and debride the wound; take a wound culture; monitor the wound
proteases; and use topical antimicrobials (silver, cadexomer iodine), systemic antibiotics
according to the antibiogram data, anti-inflammatory drugs, and protease inhibitors if
required.
It is important to monitor the exudate and achieve the equilibrium in the moisture, given that
a dry wound makes it difficult for cell migration and exudate encourages infection and
macerates the perilesional skin area. We should be aware that scarring is faster with wounds
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in an optimally moist environment in which the physiological and atmospheric conditions of
the wound bed are maintained, thus fostering basal keratinocyte migration. A moist environ‐
ment also prevents cell desiccation, encourages cell migration, promotes angiogenesis,
stimulates collagen synthesis, and facilitates intercellular communication. A moist wound
environment preserves a slightly acid pH and a low oxygen tension on the surface of the
wound [18–20].
Thus, the edges of the wound do not advance because there are keratinocytes that do not
migrate, senescent cells, and alterations in the extracellular matrix secondary to the disequili‐
brium in protease activity.
2.3. Clinical protocols
The preparation of the wound bed requires specific management protocols, which can be
grouped into three sections following the T.I.M.E. procedure:
• Nonsurgical debridement with moisture monitoring and dressing every 48 h (Table 1).
• Local infection with moisture monitoring and dressing every 72 h (Table 2).
• A granulation phase with moisture monitoring and dressing every 72 h (Table 3).
Protocol 1: (T/M= Tissue and moisture)
‐Non‐viable tissue and moisture monitoring
‐Non‐surgical debridement
‐Dressing every 48 h






‐Debridement ‐Collagenase + hydrogel ‐Collagenase ‐Cadexomer iodine + alginate
‐Moist dressing ‐Hydrocellular with acrylic
adhesive or silicone adhesive
‐Hydrocellular with acrylic
adhesive or silicone adhesive
‐Hydrocellular with acrylic
adhesive or silicone adhesive
Table 1. Preparing the wound bed: management protocol (T/M).
Protocol 2: (I/M = Infection and moisture)
‐Infection and moisture monitoring
‐Wounds with local infection
‐Dressing every 72 h































Table 2. Preparing the wound bed: management protocol (I/M).
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Protocol 3: (E/M = Edges and moisture)
‐Epithelialization of edges and moisture monitoring
‐Wounds in the granulation phase
‐Dressing every 72 h
‐Type of wound ‐Granulation tissue
‐Low or moderate exudate
‐Granulation tissue
‐High exudate
‐Granulation ‐Collagen with silver protease modulator
matrix or ‐Powder collagen
‐Collagen with silver protease modulator
matrix or ‐Powder collagen + alginate
‐Moist dressing ‐Hydrocellular with acrylic
adhesive or silicone adhesive
‐Hydrocellular with acrylic
adhesive or silicone adhesive
Table 3. Preparing the wound bed: management protocol (E/M).
After finalizing the preparation of the wound bed, the wound remains open ready for its
closure by secondary intention with granulation tissue and the re‐establishment of the
epidermis. At this point, the surgeon comes across two new problems: how to granulate the
wound, and afterwards, how to epithelialize it.
2.4. Wound granulation using negative topical pressure therapy
For the granulation, we use a noninvasive topical negative pressure wound therapy (NPWT)
(Figure 2), using aspirated drainage to eliminate the secretions, facilitate the closure and
prevent complications. Its scientific fundamentals and physiopathology are based on the
application of mechanical stress on the tissues, by creating a negative pressure on the surface
of the wound [21]. The effect of the macrotension on the tissues is carried out using a sponge
dressing (polyurethane‐polyvinyl alcohol), with open pores, that contract under the negative
pressure, bringing the edges closer together [22], eliminating the exudate, the non‐viable tissue,
and the soluble wound healing inhibitors (cytokines and matrix metalloproteinases) [23].
Other effects are a reduction in the edema, an increase in neutrophils and monocytes on the
bacterial load and an improvement in local perfusion [24]. The effect of microtension, at the
cell level, triggers cell stretching, which increases fibroblasts, the formation and division of
new cells and the rapid growth of granulation tissue [25], the migration of fibroblasts to the
area of the wound (displacing new cells to its surface), the formation of new blood vessels [26],
and the formation of granulation tissue through mitosis stimulation. In this way, moist healing
of the wound helps wound debridement (Figure 3).
The NPWT is contraindicated when either the wound has not been well explored, it has necrotic
tissue with eschar or it has weakened blood vessels due to irradiation or suture. Also, NPWT
is contraindicated in case of intestinal anastomosis, exposed nerves, the presence of tumors or
untreated osteomyelitis. Equally, it is not advisable for either enterocutaneous or enteroatmo‐
spheric fistulas. Finally, active bleeding wounds and/or patients treated with anticoagulants
are not suitable for NPWT treatment.
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Figure 2. Complex and traumatic soft‐tissue wound. Treatment with TNP therapy.
Figure 3. Complex and traumatic soft‐tissue wound. Completed granulation after TNP therapy.
2.5. Epithelialization of the chronic and complex soft‐tissue wounds
A large variety of wound coverings and procedures have become available over the past two
decades, including several types of synthetic dressings and allo‐skin or auto‐skin substitutes,
although their cost is too high for routine clinical practice [27, 28]. New technologies involving
growth factors and bioengineered tissues are relatively new and have produced relatively good
results; however, they are quite expensive.
2.6. Amniotic membrane and wound healing
Amniotic membrane (AM), the innermost layer of the placenta, has a fetal origin and can easily
be separated from the placenta by blunt dissection. AM, due to its special structure, biological
properties and immunological characteristics, is a tissue of particular interest as a biological
dressing. AM exhibits low immunogenicity and well‐documented reepithelialization effects.
Moreover, AM shows anti‐inflammatory, antifibrotic, antimicrobial, analgesic and nontumori‐
genic properties. This diversity of its effects is related to its capacity to synthesize and release
biologically active molecules including cytokines and signaling factors such as tumor necrosis
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factor (TNF)‐α, transforming growth factor (TGF)‐α, TGF‐β, basic fibroblast growth factor (b‐
FGF), epidermal growth factor (EGF), keratinocyte growth factor (KGF), hepatic growth factor
(HGF), interleukin‐4 (IL‐4), IL‐6, IL‐8, natural inhibitors of metalloproteases, β‐defensins, and
prostaglandins among others [29–31]. Moreover, AM is a biomaterial that can be easily
obtained, processed, and transported. On the other hand, AM may function as a substrate
where cells can easily proliferate and differentiate [32]. When compared to skin transplanta‐
tion, AM treatment offers considerable advantages. Its application does not produce rejection
because it has low immunogenicity and does not induce uncontrolled proliferation [33]. All
these effects are related to its capacity for the production and release of biologically active
substances (see above).
AM has been applied in medicine for more than 100 years. In 1910, Davis [34] reported a
comprehensive review of 550 cases of skin transplantation to various types of burns and
wounds using natural AM obtained from labor and delivery at the Johns Hopkins University.
In 1913, Sabella [35] and Stern [36] separately reported on the use of preserved AM in skin
grafting for burns and ulcers. Since then, there have been several reports of the uses of AM in
the treatment of wounds of different etiologies and other applications: first, in the reconstruc‐
tive surgery of different tissues and organs including the mouth, tongue, nasal mucosa, larynx,
eardrum, vestibule, bladder, urethra, vagina, and tendons [37–43]; second, as a peritoneum
substitute in reconstruction procedures of pelvic exenteration surgery; third, in adherence
prevention in the abdomen and pelvic surgery; and finally, as a covering of onphaloceles and
the like [34–37, 44].
In ophthalmology, the use of AM was reported for the first time in 1940 by De Rötth, who used
fresh fetal membranes, namely amnion and chorion, at the ocular surface as a biological
dressing in the management of conjunctival alterations [45]. Later, Sorsby et al. [46] used
preserved AM as a temporary coating in the treatment of acute caustic ocular lesions. Even
though the results were favorable, its use was abandoned for almost four decades. In 1995,
with the reconstitution assays of rabbit corneas with limbic disorder using human preserved
AM, by Kim and Tseng [47], there was a renewed widespread interest in the use of AM in
ophthalmology. Several publications appeared related to the efficacy of the AM in various
ocular surface conditions and in diseases like epidermolysis bullosa [44, 48, 49]. Nowadays,
AM is a resource widely used in ophthalmology [49–51] and to a lesser degree in the treatment
of wounds, burns lesions, and chronic ulcers of the legs [48, 52–54] and in other surgical and
nonsurgical procedures [38–43, 55–59].
3. Using AM in chronic wound healing
Once granulation of the wound is finalized, the process of epithelialization by using AM can
be initiated. The source of AM for wound healing is donated placenta. AM has been used for
wound healing either as intact AM without epithelium removal or as denuded AM, without
the epithelium, [60, 61]. In some cases, AM was used fresh, and in others AM was preserved.
Nowadays, it is known that the use of fresh AM is not practical for clinical use [62]. Methods
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to remove the epithelium or preserve AM are very diverse and exceed the scope of this chapter.
In our case, the placenta is obtained from an uncomplicated elective cesarean of a healthy
mother, excluding patients with positive human immunodeficiency virus (HIV), hepatitis B
virus (HBV), and hepatitis C virus (HCV) serology. Using an aseptic technique, AM is sepa‐
rated from the subjacent chorion by blunt dissection and stored in saline solution or phosphate
buffered saline with antibiotics (cotrimoxazol, tobramycin, vancomycin, and amphotericin B).
In this solution, AM is taken to the clean room [55]. Then, its processing, under sterile condi‐
tions, is carried out in a type II vertical laminar flow cabinet (HEPA filter). Then it is cut up
into fragments measuring 10 × 10cm, which are then placed on a sterile scaffold of sterile
petrolatum gauze (Tulgrasum®) and fixed with silk points at their ends (Figure 4). Finally,
individual fragments are introduced into a bag with cryopreservative solution to freeze them
in liquid nitrogen. These fragments cannot be used in the clinical practice until 3 months have
passed, when there is a certainty that their donor has not been seroconverted to HIV, HBV, or
HCV. After its defrosting in a 37°C bath, they are taken back to the surgical area and are applied
on the wounds of the selected patient [55] (Figures 5 and 6).
Figure 5. Complex and traumatic soft‐tissue wound. Application of the amniotic membrane.
Figure 4. Amniotic membrane fixed to sterile petrolatum gauze (Tulgrasum®) ready for its application.
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Figure 6. Complex and traumatic soft‐tissue wound. Complete epithelialization after amniotic membrane treatment.
3.1. Molecular mechanisms underlying AM‐induced skin reepithelialization
The molecular mechanisms underlying AM‐induced skin reepithelialization are largely
unknown. AM might have a wound healing effect by improving keratinocyte migration from
the wound edge and stimulating its differentiation, thereby generating an intact epithelium
[63]. Niknejad et al. [64] reflected that the stimulatory effect on epithelialization from the
wound bed and/or the wound edge is facilitated by growth factors and progenitor cells
released by AM. In addition, it has been described that the preservation of the integrity of the
basement membrane and stromal matrix increases the healing potency of AM and is crucial
in promoting a fast reepithelialization [65].
Insausti et al. [55] had previously worked on HaCaT cells, a spontaneously immortalized
human keratinocyte cell line, as a model to comprehend the molecular consequences of AM
application on human wounds [66]. This research showed that HaCaT cells exhibited different
molecular reactions upon stimulation with AM that were attributed to the effects of soluble
AM‐released factors on HaCaT cells [55]. The application of AM to keratinocytes induced the
activation of the phosphorylation of ERK1/2, JNK1/2, and p38 [55]. Also, AM‐conditioned
medium induced similar responses, suggesting a trans‐effect of AM on the triggering of these
events. Additionally, the authors reported that HaCaT cells stimulated with AM showed an
increased expression of c‐JUN. Members of the AP1 family had been involved in keratinocyte
migration and the wound healing process [67–70]. AM induced the phosphorylation of Jun N‐
terminal kinase (JNK)1 and two kinases in HaCaT cells [55]; JNK1 is a positive regulator of c‐
JUN, contributing to its phosphorylation and stabilization [71, 72]. Finally, the expression of
c‐Jun in the wounds treated with AM was very strong, and particularly evident at the basal
epithelium near the leading edge and at the dermal leading edge or keratinocyte tongue,
indicating that c‐Jun expression might be an important event for epithelialization occurring at
the AM‐stimulated wound borders [55].
3.2. Chronic wound healing, AM, and TGF‐β
Wound fluid derived from chronic venous leg ulcers is rich in pro‐inflammatory cytokines
such as TNF‐α, interleukin‐1β (IL‐1β), and TGF‐β1 [73]. In addition, the quantities of these
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cytokines drop as the chronic wound commences to heal, denoting a strong correlation
between non‐healing wounds and an increased level of pro‐inflammatory cytokines [74]. TGF‐
β has a critical role in regulating multiple cellular responses that occur in all phases of wound
healing [75]. Of the many cytokines shown to influence the wound healing process, TGF‐β has
the broadest spectrum of action because it affects the behavior of a wide variety of cell types
and mediates a diverse range of cellular functions [76]. Platelets are thought to be the primary
source of TGF‐β at the wound site; also, activation of latent TGF‐β occurs immediately after
wounding [75]. The TGF‐β signaling pathway is considered as a promising target for the
treatment of many pathological skin conditions including chronic non‐healing wounds [75].
Keratinocytes, fibroblasts, and monocytes are among the targeted cells in the TGF‐β manage‐
ment of the wound [76]. Monocytes/macrophages and fibroblasts then contribute to autocrine‐
perpetuated high concentrations of TGF‐β at the wound site [76].
TGF‐β exerts its effect on cells by increasing the phosphorylation of members of the receptor
activated (R‐)Smad family (Smad2 and 3). Additionally, non‐Smad pathways are also activated,
including the extracellular‐signal‐regulated kinase (ERK), JNK, and p38 mitogen‐activated
protein (MAP) kinase pathways, the tyrosine kinase Src, and phosphatidylinositol 3‐kinase
(PI3K) [77, 78]. Once receptor‐induced phosphorylation has taken place, R‐Smads form
complexes with the common‐mediator (Co‐) Smad4, which are translocated to the nucleus [79]
where they, in cooperation with other transcription factors, co‐activators, and corepressors,
regulate the transcription of specific genes [80].
The effects of TGF‐β on full‐thickness wound reepithelialization have been studied in a
transgenic mouse. The study in the ear mouse model suggests that TGF‐β has an inhibitory
effect on epithelialization when the wound involves all the layers of the skin [81]. Also, the
overexpression of TGF‐β, at the epidermis level, causes a decrease in reepithelialization [82,
83]. Abolishing part of the TGF‐β signaling pathway has been suggested as a way to improve
wound healing, so abolishing part of the TGF‐β‐stimulated Smad pathways may enhance
wound healing and benefit the effect of TGF‐β signaling over matrix synthesis by fibroblasts,
for instance [76]. TGF‐β causes the growth arrest of epithelial cells. The mechanisms, which
differ somewhat between different cell types, involve the inhibition of the expression of the
transcription factor Myc and members of the Id family, and the transcriptional induction of
the cell cycle inhibitors CDKN2B (p15) and CDKN1A (p21) [84].
In order to further unravel the molecular mechanism by which AM may contribute to the
epithelialization and wound border proliferation in chronic post‐traumatic wounds, Alcaraz
et al. [85] analyzed the association between TGF‐β signaling and AM regulation in wound
healing using keratinocytes. Strikingly, AM was capable of attenuating the TGF‐β‐induced
phosphorylation of Smad2 and Smad3 in HaCaT cells. Both the strength and duration of TGF‐
β signaling, expressed as sustained phosphorylation of Smads, are essential to achieve proper
cell responses to TGF‐β; the impossibility to do so produces a loss of the cell cycle arrest in
response to TGF‐β [86]. AM attenuates TGF‐β‐induced Smad2 and Smad3 phosphorylation
and hence attenuates CDKN2B (p15) and CDKN1A (p21) expression [85], which has been
connected to cell cycle regulation [86]. Therefore, the presence of AM counteracts the cell cycle
arrest induced by TGF‐β on keratinocytes, releasing them from the restrain imposed by TGF‐
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ß [85]. The effect of AM on TGF‐β‐regulated genes is not indiscriminate, and not all genes are
affected by the presence of AM. Interestingly, genes that positively participate in wound
healing such as SNAI‐2 and PAI‐1 were synergistically up‐regulated by the presence of AM
and TGF‐β [85]. Finally, the expression of c‐Jun was maximal when both TGF‐β and AM were
present in either HaCaT or primary keratinocyte cells [85].
It has been suggested that AM might exert its wound healing effect by increasing keratinocyte
migration speed from the wound edge [63]. Growth factors and progenitor cells released by
AM [64] are supposed to mediate the epithelialization stimulatory effect. AM induces cell
migration in a wound healing assay in keratinocytes and mesenchymal cells [85]. Furthermore,
in keratinocytes, inhibition of cell proliferation with mitomycin C, affected the migrating
properties of AM. In the same study, the use of JNK1 inhibitors prevented AM‐induced cell
migration in both cell types. Moreover, a closer inspection of the margins of the scratch wound
healing assays showed a high expression of c‐JUN in the AM‐stimulated cells engaged in the
migratory wave. The AM‐induced high expression of c‐JUN at the wound border was
prevented by inhibitors SP600125 and PD98059, which is consistent with the fact that AM
induces the activation of a signaling cascade that produces the phosphorylation of ERK1/2 and
JNK1/2. A local increase of c‐JUN was observed in the patient wound border when the wound
had been treated with AM. This is coherent with the AM effect on cell migration. In fact, in the
examination of patient wound borders a few days after AM application, a clear proliferation/
migration was observed [85]. This correlates well with the robust expression of c‐Jun at the
wound border, which is particularly robust at the stratum basale of the epidermis that overlaps
the keratinocyte tongue, the area where the migration of keratinocytes happens to epithelialize
the wound [85]. Additionally, in that investigation, the authors revealed that the application
of AM promotes healing in chronic wounds by refashioning the TGF‐β‐induced genetic
program, stimulating keratinocyte migration and proliferation [85]. Additionally, there might
be a synergy of AM and TGF‐β signaling for the resolution of chronic wounds [85, 87]. Thus,
stimulation of keratinocytes with both AM and TGF‐β was synergistic when compared to both
stimulus being added separately [85]. Moreover, the treatment of cells with TGF‐β signaling
inhibitors hampered the effect of AM, indicating that both AM and TGF‐β signaling positively
contribute to cell migration [87]. The down‐regulation of Smad3 has been suggested as a
possible way of improving wound healing [76]. In this sense, the effect of R‐Smads, Smad2 or
3, seems to be different given that the overexpression of Smad2 increased AM‐induced cell
migration while the overexpression of Smad3 prevented it [87]. Notably, the ability of kerati‐
nocytes to sense TGF‐β through Smad3 prevents the cell proliferation of keratinocytes and
consequently prevents wound healing resolution when the levels of TGF‐β are high [88].
Presently, in order to evaluate the effect of AM on chronic post‐traumatic wounds, a clinical
trial is being conducted in our hospital, with exceptional results. The TGF‐β‐stimulated Smad
pathway has also been involved in the production of fibrosis and inflammation in response to
TGF‐β. Thus, interfering with TGF‐β signaling may be a good way of interfering with fibrosis
and improving the evolution of wound healing [76]. In different experimental models, the
application of AM is able to ameliorate fibrosis [89–92]. Currently, we are exploring whether
the application of AM is able to reduce fibrosis and inflammation in chronic wounds.
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4. Summary
To summarize, AM is a biological dressing that stimulates proper epithelialization in chronic
wounds. It has several advantages; among them, it is economical, easy to obtain, and in endless
supply. Additionally, AM can be cryopreserved at a low temperature while preserving all its
biological functions. Finally, it can be used as a treatment in the outpatient clinic, which reduces
costs even more. Thus, AM must be taken into account as a consolidated treatment option for
chronic wounds.
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